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Abstract
We investigated the ability of diamond nanoparticles (nanodiamonds, NDs) to deliver
small interfering RNA (siRNA) in Ewing sarcoma cells, in the perspective of in vivo
anti-cancer nucleic acid drug delivery. siRNA was adsorbed onto NDs previously coated
with cationic polymer. Cell uptake of NDs has been demonstrated by taking advantage
of NDs intrinsic fluorescence coming from embedded color center defects. Cell toxicity of
these coated NDs was shown to be low. Consistent with the internalization efficacy, we
have shown a specific inhibition of EWS/Fli-1 gene expression at the mRNA and protein
level by the ND vectorized siRNA in a serum containing medium.
1 Introduction
In the anti-cancer drug delivery domain, nanotechnologies are a promising tool for fu-
ture applications such as a more favourable tissue distribution and a decrease of the
toxicity.1Various types of nanoparticles have been developed2 such as liposomes, lipidic
micelles, dendrimers and polymers. Active molecules are either covalently bound to the
nanoparticles,3,4 adsorbed onto their surface5,6 or encapsulated.7
The requirements for the efficacy of a vector are (i) a large quantity of active molecules
per vector entity, (ii) the capacity to reach the targeted cells, (iii) the capacity to deliver
the active molecule to the target in these cells. As far as side effects are concerned
the nanoparticle needs to have a low toxicity, to be bio-compatible, and to be quickly
eliminated from the body after their action has taken place. Therefore, in order to find the
most potent compounds a large variety of vectors needs to be investigated. For instance
the use of mineral nano-object as carrier for drug delivery has been proposed including
silica, metals, and carbon.4,8–10
In this work we used diamond nanocrystals (nanodiamonds)11,12 as a cell targeting bi-
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functional device, serving as a drug delivery vehicle and a fluorescent label at the same
time. Nanodiamond display attractive properties such as a small size, down to less than
10 nm, various possibilities of surface funtionnalization13 and a perfectly stable photolu-
minescence well adapted for studying intracellular traffic and localization. The fluores-
cence properties results from the creation of nitrogen-vacancy (NV) color centers inside
the nanodiamond matrix. The nitrogen is naturally present in synthetic diamond pro-
duced under high-pressure and high temperature conditions. The vacancy is created by
high-energy ion beam irradiation, and the NV complex is formed after thermal annealing.
Various approaches have been recently reported for the production of bright fluorescent
nanodiamonds (fNDs) in quantities sufficiently large for the need of bio-applications.14–16
Compared to semiconductor nanocrystals (QDots), NV color centers contained into NDs
present a perfectly stable emission (no blinking, no bleaching), with a similar brightness
at saturation of their fluorescence.17 They can therefore be used for long-term tracking
in cells and organisms.15,18
Furthermore, NDs seem to be better tolerated by cells than other carbon nanomateri-
als.19 Fluorescent NDs introduced into Caenorhabditis elegans worm, by either feeding
or microinjection into the gonads proved to be stable nontoxic and did not cause any
detectable stress to the worms.18 In mice, intravenous injection of 50 nm size NDs led
to longterm (28 days) entrapment in the liver and the lung,20 but no mice showed any
symptoms of abnormality. However, further toxicological studies are necessary due to the
accumulation. Moreover, when instilled in the mouse trachea 4 nm NDs did not show
evident adverse effects in the lungs, owing to their efficient elimination by macrophages.21
Considering these encouraging results in cellular and small animal models, in vitro experi-
ments have been recently performed with NDs to show their capacity to deliver anticancer
drugs, in cell3,22 and in mouse model of liver and mammary cancers where ND delivery
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enhances the chemotherapeutic efficiency of the drug.23
Recent studies have shown the potential of nanodiamonds coated by cationic polymers to
deliver genes into the cells,5 including siRNA,24 without adverse effects, and with higher
efficiency than the standard lipofectamine transfecting agent in physiological conditions.
siRNA are short double strand RNAs inducing gene-silencing activity by interfering with
mRNA in the cell cytoplasm by triggering a sequence specific cleavage at the level of
sequence recognition on target mRNA after association to the RISC complex.25
In this work we establish the relevance of such a strategy in a therapeutic context. We
used NDs as a cargo to deliver siRNA in human cell lines originating from Ewing Sar-
coma tumors. Ewing Sarcoma, a genetic disease considered as the most frequent bone
cancer in children, is induced in 90% of case by chromosomal translocation at the level of
chromosomes t(11,22). This results in EWS-Fli1 fusion gene, which is finally expressed
as a chimeric protein.26 Treatment of this cancer involves surgical resection, radiotherapy
and chemotherapy. New strategies based on the inhibition of EWS-Fli1 gene by antisense
oligonucleotides or siRNA targeting the EWS-Fli1 junction at the mRNA level have been
developed.27 siRNA were shown to trigger the EWS-Fli1 mRNA cleavage and showed
an inhibition in vitro of EWS-Fli1 expression and in vivo of tumor growth.28–31 Despite
their high in vitro efficiency siRNAs are quickly degraded in physiological fluids and have
a poor capacity as polyanions to enter cells. Their in vivo efficiency can therefore be
greatly improved by the use of cargo delivery systems.31–33
We developed cationic NDs able to bind siRNAs at their surface. We compared two types
of polymers capable of interacting with anionic oligonucleotides polyethylene-imine (PEI)
and polyallylamine hydrochloride (PAH). PEI is currently used as an oligonucleotide
transfection agent. However, the water-soluble PEI does not form siRNA polyplexes
stable enough in extracellular media for effective delivery, but the system consisting in
noncovalent coating of PEI to the surface of a nanoparticle has proved to be a very
efficient DNA and siRNA delivery device.5,24,34 We also used PAH coating because it was
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shown to form a reproducible complex leading to a stable aqueous suspension with a low
cell toxicity.35
Herein, we analyzed the data obtained with these two types of coating, using fluorescent
NDs, in terms of their capacity (i) to bind to siRNA, (ii) to allow its cell uptake, and (iii)
to inhibit EWS-Fli1 expression in cell culture at both the mRNA and protein levels.
2 Results and discussion
2.1 Characterization of cationic nanodiamonds
Both types of ND (as received powder, or electron irradiated and annealed ones) have
undergone an oxidative treatment to remove the graphitic shell, resulting in a surface
rich in carboxylic groups, and forming anionic particles. Cationic NDs were produced
by surface coating with amino rich polymers: Poly(allylamine hydrochlolide)(PAH) red,
following our previous work procedure,35 or Polyethileneimine (PEI). As indicated in Ta-
ble 1, the pH are 5.6 and 6.7 for ND-PAH and ND-PEI aqueous suspensions respectively.
ND zeta potential shifts from -27 mV before polymer coating to +31 mV or +26 mV
after coating by PAH or PEI, respectively. This surface coating is associated to an in-
crease of their size from 50 nm to 130 nm and 120 nm respectively, which is most likely
due to the formation of small aggregates during the coating. When the particle charge
turns from negative to positive value, repulsion between particles is lower, and aggre-
gation is generally observed. It is well known that nanoparticles have a propensity to
form strongly bound aggregates hard to break even by strong sonication. However beads
assisted sonication has recently been successful for de-agglomeration and simultaneous
covalent functionalization of nanodiamonds at their primary particle level.36
FT-IR spectroscopy reported in a previous study35 confirms the adsorption of PAH on
nanodiamonds. For PAH and PEI coated NDs, the quantity of the amino group was
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determined by the Kaiser methods to be 274 and 173 µmole per gram of NDs, respectively.
However, in the latter case this amount is underestimated, as the tertiary amines present
on a branched PEI (25% of the total amino groups) do not react with the ninhydrin.
2.2 Adsorption of siRNA onto cationic ND: determination of
the concentrations at saturation
The siRNA adsorption capacity of the polymer-coated NDs has been measured by adding
a siRNA solution at the smallest concentration compatible with the quantification method,
i.e. 5 ngµl−1 (corresponding to 384 nM) with increasing concentrations of NDs (0-
0.4 µgµl−1). The adsorption of siRNA do not lead to increase of hydrodynamic radius
of the nanodiamond complex, despite a decrease of the zeta potential to about +10 mV.
After centrifugation, the free nucleic acid concentration is determined by fluorescence of
the supernatant fractions after ethidium bromide coloration. Figure 1 shows the sat-
uration curve obtained with as-received anionic NDs, and cationic PAH- or PEI-coated
NDs. A decrease of the free nucleic acid content is observed when cationic polymer-coated
NDs are added to the siRNA with increasing concentrations, while no change happens
with the as-received anionic NDs, as expected from charge repulsion. The saturation
of siRNA adsorption onto ND-PAH happens at ND-PAH concentration of 0.35 µgµl−1,
corresponding to a siRNA:ND-PAH mass ratio of 1:70 and a phosphate to amino groups
charge ratio of 1:6. In the case of ND-PEI solutions we also observe a decrease of the
free siRNA upon increase of the ND concentration, but the siRNA charges are never fully
compensated by ND-PEI positive charges in the concentration range explored. At the
maximal ND concentration of 0.4 µgµl−1, the mass ratio of free siRNA to ND is 1:120
associated to a 1:4 charge ratio. However, siRNA total adsorption onto ND-PEI can be
extrapolated from a linear fit of the curve and corresponds to concentration of 0.7 µgµl−1
associated to a saturation mass ratio of 1:140 and a phosphate to amino charge ratio of
1:8. The conclusion is that at a given ND concentration, ND-PAH is able to adsorb a
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higher amount of siRNA than ND-PEI. Note that the slightly larger zeta potential of
ND-PAH compared to that of ND-PEI also supports this conclusion.
2.3 Cytotoxicity of the ND on NIH/3T3 cells
In order to evaluate the toxicity of the nanodiamond, we have studied the cell viability
of NIH/3T3 murine fibroblasts in the presence of NDs, NDs coated with the polycations
(PAH or PEI), and ND-siRNA complexes. In the latter case, the typical concentration
of 50 nM of siRNA was used.37 Figure 2 shows that only ND-PAH, non complexed with
siRNA, presents some toxicity, but at a high concentration with a IC50 of 0.1 µgµl−1.
This effect might be due to cationic charges at the ND surface, as it has already been
observed with polycation-coated silver nanoparticles.38 When the cationic charge is neu-
tralized by siRNA adsorption, the toxicity decreases. The relative decrease is larger in the
case of PAH coating, since PAH is more toxic than PEI. However, for all ND-siRNA com-
plexes the cell viability is larger than 70%, even at the maximal concentration used. These
results have to be compared to a 45% toxicity which is observed after cell incubation with
Lipofectamine siRNA lipoplexes at a dose corresponding to 50 nM siRNA final concen-
tration (see Supporting Information) in conditions recommended by the supplier (serum
free medium for 3 hours followed by 21 hours of culture in complete medium).
Cytotoxicity studies were also performed on cells expressing the EWS-Fli1 oncogene, i.e.
the murine fibroblast NIH/3T3 EF cells and the A673 human cells (see Supp. Info.).
This later study allowed us to select the concentration range of siRNA-cationic NDs with
a toxicity low enough not to interfere with the inhibition effect sought. Similar results
were obtained, i.e. concentration lower than 0.1 µgµl−1.
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2.4 siRNA delivery into cells by cationic fluorescent nanodia-
monds
Cellular uptake efficiency and intracellular distribution of the siRNA-ND complexes have
been evaluated using the fluorescence of FITC-labeled siRNA and that of fNDs. Figure 3
displays a cell observed by confocal microscopy after 4 hour incubation with siRNA
complexed to ND-PAH or ND-PEI. The signal in the red channel appears to be perfectly
stable in time, which is a characteristic of fNDs fluorescence. As observed in previous
studies nanodiamonds are localized in the perinuclear region and do not enter into the
cell nucleus.17
For the given siRNA concentration of 50 nM, the ND-polycation mass was optimized to
yield a sufficient amount of internalized nanoparticles as estimated from the intensity of
the fND and FITC-labelled siRNA fluorescence signal (see Supp. Info.). The optimal
siRNA:ND mass ratios were found to be 1:25 for ND-PAH and 1:75 for ND-PEI, corre-
sponding to a 0.016 µgµl−1 and 0.048 µgµl−1 respectively. These ratios correspond to
ND mass below the ones of the measured saturation values of 1:70 and 1:140 for ND-PAH
and ND-PEI respectively, which means that the siRNA-ND complex is saturated in both
cases. Moreover, no FITC-labelled siRNA is observed inside the cell if it is not adsorbed
onto a cationic nanodiamond carrier (Figure 2(a) of Supp. Info.), as well known.
Figure 3 shows a strong colocalization between FITC labelled siRNA and the fNDs,
at time t = 24 h after the 4 h incubation with siRNA:ND-PEI complex and change of
medium to remove extra ND complexes. ImageJ JACoP pluggin39 was used to plot the
green channel intensity (FITC) vs. the red channel one (fNDs). Despite difference in
mean intensities of the two channels, Figure 3(c) scattered plot distribution indicates
a some colocalization. JACoP pluggin also allows to quantify the fraction of red (resp.
green) channel overlapping the green (resp. red) one, with Manders’ coefficients M1
(resp. M2), taking as the threshold the onset of cellular autofluorescence on each channel
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(3σ below the mean value of the autofluorescence intensity). Values M1 = 0.63 and
M2 = 0.96 were obtained, confirming a high degree of colocalization. This results indicate
that siRNA is not released in the form of large aggregates, but rather as small ones not
detectable due to a fluorescence intensity of the same order of magnitude than the cell
autofluorescence.
In order to evaluate the dynamics of the release in cell of siRNA from the fNDs, we did
confocal scans of cell cultures fixed at five different times (from 6 to 72 h), after the 4 h
initial incubation duration with the NDs. For this study we used FITC-labeled siRNA
complexed to fND-PAH (resp. fND-PEI) at the optimal mass ratio of 1:25 (resp. 1:75).
At t = 6 hours, Figures 4(a) and (b) show a strong signal of FITC at the same position
than fND, indicating that siRNA are still bound to NDs. The FITC signal centered on
the fNDs signal then drastically decreases in the case of PEI to stabilize at its lowest
value at 24 h, while it only very slowly decreases for ND-PAH (Figure 4(c)).
Further studies have shown that NDs-polycation siRNA are internalized in Ewing sarcoma
cells by endocytosis (data not shown). One hypothesis to account for the efficiency of
polycations bearing amino groups as oligonucleotide delivery vehicles, is that they trigger
the endosome disruption before the complex is transferred to the acidic lysosome com-
partment. The proposed mechanism relies on the protonation of the amino-polycation
inside the cell due to its large pKa (pKa' 9 for PEI40), leading to an influx of counter-ions
resulting in osmotic swelling followed by endosome membrane disruption and cytoplas-
mic release of the oligonucleotide-polycation complex.34,41 Furthermore, in our case, the
affinity of siRNA for ND-PAH being stronger than for ND-PEI, the desorption of siRNA
from the nanodiamond carrier in the cytosol happens to be slower in the case of PAH
coated ND.
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2.5 Inhibition of EWS-Fli1 by cationic ND vectorized siRNA
The efficiency of siRNA vectorized by cationic NDs has been evaluated by their ability
to interfere destructively with the targeted EWS-Fli1 mRNA involved in Ewing sarcoma.
After cell treatment with 50 nM EWS-Fli1 siRNA vectorized either by ND-PAH or ND-
PEI, we have measured by qPCR the EWS-Fli1 mRNA ratio in treated and untreated
cells as described in the Experimental Section. The capacity of siRNA to inhibit mRNA
expression was tested with the two cell lines expressing EWS-Fli1: NIH/3T3 EF and
A673. Figure 5(a) shows that 50 nM free siRNA do not inhibit EWS-Fli1 expression.
When it is vectorized by either ND-PAH or ND-PEI, EWS-Fli1 mRNA expression is
inhibited, with the maximum efficiency of 50% for ND-PEI in the case of NIH/3T3 EF
cells and resp. 55% with A673 cells (Figure 5(b)). ND-PAH appears to be a less
efficient transfection agent. In the same conditions a control siRNA, with no anti-sens
action, gives no inhibition effect.
When Lipofectamine R© is used to vectorize the same quantity of siRNA in a free serum
medium, we obtained 65% inhibition of the targeted mRNA, but associated to a 50%
cytotoxic effect compared to only 20% for ND-PAH or ND-PEI. Moreover, if the cells are
treated by Lipofectamine in serum containing medium, the inhibition of EWS-Fli1 mRNA
expression is only 20% to be compared with 50% for ND-PEI vectorized siRNA, proving
that ND-PEI is a better transfection agent for siRNA in physiological conditions.
To confirm the specific EWS-Fli1 inhibition by nanodiamond-vectorized siRNA, we have
determined the protein expression by a Western blot assay, using the A673 cell line. As
shown on Figure 5(c) a specific inhibition of EWS-Fli1 oncogenic protein takes place
with siRNA vectorized by ND-PEI at a mass ratio of 1:75. No effect is observed on
β-actin used as house-keeping protein. By using siRNA:ND-PAH at a mass ratio of 1:25
inhibition of EWS-Fli1 protein expression can hardly be observed, which is consistent
with RT-qPCR data.
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The larger inhibition efficiency of siRNA:ND-PEI compared to siRNA:ND-PAH is also in
perfect agreement with a slower release of siRNA in the later case, as observed in confocal
microscopy (Figure 4).
3 Conclusions
We have synthesized a fluorescent nanodiamond vector with two different cationic coat-
ings, for siRNA delivery into Ewing sarcoma cell in culture. This vector shows advantages
compared to the usual transfection agent lipofectamine, inducing a larger efficiency in in-
hibiting the EWS-Fli1 expression, combined with a lower toxicity to the cell in serum
supplemented medium. We observed that the larger adsorption affinity of siRNA onto
PAH-coated NDs than onto PEI-coated NDs results in a much slower dissociation of the
siRNA:ND-PAH complex than of the siRNA:ND-PEI ones, and hence a lower siRNA-
associated biological activity. Moreover, we showed that the ND-PEI carrier is less toxic
than the ND-PAH ones.
This study shows that the efficient delivery of an oligonucleotide by a cationic solid
nanoparticle consists in a compromise between (i) a sufficiently strong adsorption of the
biomolecule onto the particle to go through the cell membrane without loss of material,
(ii) the dissociation of the complex on the timescale of a cell division cycle, and (iii) a
low cellular toxicity. Furthermore a careful selection of the cationic polymer may even
serve to control the release kinetics of the siRNA.
The next step will be to test the activity of the siRNA delivered by the cationic NDs
in vivo and study the elimination of the vector. The biodistribution, the toxicity, and
pharmacokinetics studies of this new vector will be facilitated by its fluorescence proper-
ties.
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4 Experimental Section
ND-polycation complex formation and characterization (ND surface functionalization by
polycation, siRNA adsorption): This procedure was optimized using as-received, non
fluorescent nanodiamonds first, of an average size of 50 nm (SYP 0-0.05, 50 nm; Van
Moppes, Geneva, Swizerland). These particles are cleaned in a strongly oxidative acid
mixture by the manufacturer. Their dispersion in water yields a colloidal suspension with
negative zeta potential values as reported in Table 1. This is attributed to carboxylic
acid groups at the diamond surface,42 further confirmed by FTIR analysis displaying a
broad band centered at 1775 cm−1 (C=O stretching bond).43
As-received NDs were dispersed in deionized water to achieve a 1 g l−1 concentration.
The suspension was sonicated 3 h, at 300 W (Vibra-Cell with a 3 mm stepped mi-
crotip) to ensure de-agglomeration. We used branched low molecular weight (800 Da)
Polyethylenimine (PEI), ethylenediamine end-capped (Sigma-Aldrich Ref. 408719) and
Poly(allylamine hydrochlolide) (PAH, Sigma-Aldrich Ref. 283215) polycations. To ad-
sorb the polymers on NDs, 1 g l−1 NDs water solution was added dropwise to a PAH
solution (v/v) (1 g l−1, 3 mM NaCl) or to PEI solution (at the ND particle:PEI molar
ratio 1:10, like in Zhang et al. 5) and then strongly sonicated at power 300 W, for 15 min.
The mixtures were stirred overnight at room temperature, then washed 3 times with
deionised water and centrifugated at 25,000 rpm for 1 h (Optima XL90 Ultracentrifuge,
50Ti rotor, Beckman Coulter, Inc., USA). The ND-Polymer pellet was redispersed in
water, and the concentration was determined by weighting after lyophilization of 1 ml of
the solution.
The size of the ND and ND-polycation complex were determined by dynamic quasi-elastic
light scattering (Nano ZS, Malvern Instrument, UK). The measurements were done at
20◦C, using an aqueous solution of NDs at the concentration of 20 µg ml−1. The zeta
potential was determined with the same instrument using a solution of NDs in 1 mM
NaCl at the concentration of 80 µg ml−1. Both the size and the zeta potential values are
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reported in Table 1 and correspond to the average of three measurements.
After coating by PAH or PEI, the quantity of amine associated to the NDs was deter-
mined by the Kaiser method44 as described by Vial and al.35 Briefly, we added to 100 µl of
dried amino-substituted NDs, 75 µl of phenol/ethanol solution (8 g in 2 ml), 100 µl pyri-
dine/KCN solution (98 ml pyridine in 2 ml of 1 mM KCN) and 75 µl ninhydrin/ethanol
solution (1 g in 20 ml). The solution was heated at 100◦C for 5 min and diluted with the
addition of 2 ml of ethanol. The solution was centrifugated during 5 min at 13,000 rpm
to remove the NDs particles. The amine concentration in the supernatant is inferred
from the light absorption coefficient at the wavelength of 570 nm. The quantity of amine
present is expressed in µmole g−1 of ND suspension using ε=19,700 M−1cm−1 as the molar
extinction coefficient.
PEI or PAH coated nanodiamonds at increasing concentration (0 to 0.4 µgµl−1) were
incubated with a constant concentration of siRNA (5 ngµl−1 for 15 min at room temper-
ature. In order to determine the remaining free siRNA concentration, the solution was
first centrifugated at 13,000 rpm during 30 min, then 10 µl aliquot of supernatant was
mixed with 10µl ethidium bromide (EtBr) at 2 µgµl−1 concentration. The EtBr fluo-
rescence was quantified under UV illumination with a gel imaging and analysis system
(InGenius, Syngene, UK) using 5µl drop of the mixture.
Cellular studies (cell culture and viability, cell transfection): The NIH/3T3 cells express-
ing human EWS-Fli1 oncogene is a generous gift from Dr. J. Ghysdael (Institut Curie,
Orsay, France). These cells were grown in DMEM medium (Gibco R©, Invitrogen Corp.,
USA) containing 10% newborn calf serum (Gibco), 1% penicillin-streptomycin antibiotics
(Gibco) and 2.5 µgµl−1 Puromycin (Sigma-Aldrich, USA). Incubation was performed at
37◦C, 5% CO2 in a moist atmosphere. A673 human Ewing sarcoma cells were a generous
gift from Dr. Elizabeth R. Lawlor (University of Michigan, USA) and were grown in
DMEM medium supplemented by 10% of foetal bovine serum (Gibco) and 1% penicillin-
streptomycin antibiotics (Gibco).
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Cell viability in the presence of polycation-coated NDs was determined on regular NIH/3T3
cell line by MTT test (Sigma-Aldrich). Cells, plated within 96 wells (TPP, Dominique
DUTSCHER SAS, France) with 2 × 104 cells in 100 µl of full medium per well, were
incubated with nanodiamonds at indicated doses during 24 h at 37◦C. Then, 10 µl of
5 mg ml−1 MTT in PBS was added to the culture during 2 h. Cells were then lysed
by 100 µl of 10% sodium docecyl sulfate and 10 mM HCl solution over night. The
absorbance of the formazan produced was measured at 570 nm wavelength on a plate
reader (MRX2TM, Dynex Technologies, USA). Results are expressed in percentage using
untreated cells as the residual absorbance reference.
The effect of siRNA was measured after its cell transfection with ND-PAH or ND-PEI.
The siRNA sequences were designed to target the oncogene junction EWS-Fli1 in the
chimeric mRNA (nucleotides 822-842). The siRNAs with the following sequences were
purchased from Eurogentec (Lie`ges, Belgium):
siRNA antisense: sense strand 5’-r(GCUACGGGCAGCAGAACCC)d(TT)-3’,
antisense strand 5’-r(GGGUUCUGCUGCCCGUAGC)d(TG)-3’ ;
siRNA control: sense strand 5’-r(GCCAGUGUCACCGUCAAGG)d(AdG)-3’,
and antisense strand 5’-r(CCUUGACGGUGACACUGGC)d(TdT)-3’.
The sense and antisense strands were hybridized at 20 µM concentration in annealing
buffer (Eurogentec) by heating 5 min at 95◦C followed by 1 h at 37◦C. NIH/3T3 EF
or A673 cells were seeded into 12 wells plates at the density of 1.5 × 105 cells per well
in 500 µl of corresponding medium 24 h before transfection. Different mass ratios of
ND/siRNA antisens and control were prepared as following. siRNA were prepared at
250 nM concentration in 100 mM NaCl, 10 mM Hepes buffer (pH=7.3). A volume of
40 µl of this solution was mixed with 60 µl of ND-PAH or ND-PEI prepared in 100 mM
NaCl, 10 mM Hepes buffer, at different concentrations of nanodiamonds. The mixture was
incubated during 15 min at room temperature to form the ND/siRNA complexes. The
medium in each well was finally replaced with 400 µl of fresh culture medium containing
serum and 100 µl of the complexes. Cells where then incubated for the time indicated in
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each experiment.
Fluorescence Microscopy (synthesis of fNDs, cell imaging): fNDs were prepared according
to Dantelle et al.16 procedure. Briefly, vacancies were created in diamond nanocrystals
(size< 50 nm, SYP0-0.05, Van Moppes) by a electron beam irradiation (energy: 13 MeV).
NV centers were formed upon annealing in vacuum (800◦C, 2 hours), leading to the
migration of the vacancies in the diamond matrix and their stabilization in adjacent sites
of a nitrogen impurity in substitution. The graphitic shell formed on ND surface during
this process was finally removed by air oxidation.45 The NV color center (hence fNDs)
emission spectrum spans from a wavelength of 600 to 750 nm.
The cells were plated in 12-wells plates (1.5 × 105 cells and 500 µl of medium per well)
with a cover glass (18 mm in diameter) at the bottom of each well, and cultured during
24 h. fND-PEI or fND-PAH were complexed with fluorescently labelled siRNA (3’-FITC-
siRNA antisense, from Eurogentec) at the concentration of 50 nM siRNA, and at different
siRNA:ND weight ratios from 1:25 to 1:75. The cell medium was replaced by 100 µl of
the fND-siRNA complex solution, completed by 400 µl of serum free OptiMEM medium
(Gibco) in each well. After 3 h of incubation, cells were washed by PBS, and then fixed
with paraformaldehyde 4% in PBS during 20 min at room temperature. After two washes
with PBS, slides were mounted with Dapi Fluoromount G (Southern Biotech) and then
observed with confocal microscopy (TCS SPE Leica coupled to a DMI 4000B Leica mi-
croscope). The green channel corresponds to the 501-543 nm spectral region, while the
red one is associated to the 654-702 nm wavelength range. For the quantification of the
kinetics of siRNA release, the intensities of both channels was calculated using NIH Im-
ageJ software. It can be assumed that that only FITC-labeled siRNA bound to the fNDs
contributes to the green intensity, since when siRNA were released they spread all over
the cytosol, and FITC signal at each pixel could not overcome autofluorescence intensity.
Colocalization studies of fNDs and siRNA were realized on a home-made scanning stage
confocal microscope described in Faklaris et al.17 equipped with single-photon counting
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detectors.
Biological activity tests(Real-Time quantitative PCR, Inhibition of Proteins synthesis) :
The total RNA extraction was performed as following. After 24 h incubation, cells were
washed with PBS and lysed with 800 µl TRIzol (Invitrogen). Note that this procedure
only keep live cells, dead cells being washed away. Then, 160 µl of chloroform was
added, and the mixture was centrifugated at 13,000 rpm for 15 minutes. A volume
of 300-350 µl of the aqueous phase was mixed with the same volume of isopropanol,
incubated for 15 min at room temperature and centrifuged at 13,000 rpm for 15 min at
4◦C. The pellet was washed twice with 70% ethanol, dried at room temperature, and
then dissolved in 10 µl of water containing 0.5 unitµl−1 RNasin R© (Promega Corp., USA)
ribonuclease inhibitor. The total amount of RNA was quantified using spectrophotometry
(UV1605, Shimadzu Corp., Japan) at the wavelength of 260 nm. Reverse transcription
was performed on 1.5 µg of total RNA by adding 2 µl of Random Hexamers at 50 µgµl−1
(Promega), and heating at 65◦C during 5 min. Then RNA was incubated with 0.5 µl M-
MLV Reverse Transcriptase 200 unit/µl, 0.5 µl dNTP 20 mM, 0.5 µl RNasin 40 unit/µl
and 4 µl of M-MLV RT 5× reaction buffer (Promega) for 1 h at 42◦C. Quantitative PCR
was performed using SYBR GreenER qPCR SuperMix (Invitrogen). EWS-Fli1 gene
was amplified using EWS-Forward Primer: 5’-AGC AGT TAC TCT CAG CAG AAC
ACC-3’ and Fli1-reverse primer: 5’-CCA GGA TCT GAT ACG GAT CTG GCT G-3’
(Eurogentec). One µl of each primer at 10 µM was mixed to 5 µl of cDNA diluted to
1/20 (v/v) in 25 µl final volume. Samples were amplified with 45 cycles using 7900HT
Fast Real-Time PCR System (Applied Biosystems, USA) as follows: 2 min incubation
at 50◦C, 10 min at 95◦C, followed by 45 cycles at 95◦C during 15 s and 60◦C during
1 min. Human 18S gene was used as a PCR reference gene, using 18S forward primer
5’-CGT TCA GCC ACC CGA GAT-3’, and 18S reverse primer 5’ TAA TGA TCC TTC
CGC AGG TT-3’. The quantification cycle (Cq) is between 10-16 for 18S gene and 20-24
for EWS-Fli1 gene. The results are expressed as a percentage compared to untreated
cells. The whole process starts with live cells, and is therefore insensitive to the toxicity
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of the siRNA:ND-polycation complex, although a low toxicity is desirable for a better
quantification.
Proteins extracts were obtained from 3 × 105 cells per well, grown in 6 wells plates and
incubated during 24 h with different weight ratio of ND/siRNA. The cells are lysed using
200 µl RIPA Buffer (50 mM Tris pH=7.4, 150 mM NaCl, 1 mM EDTA, 10% Glycerol,
0.5% NP40 and complete protease inhibitor (Roche, Germany). After cell lysis, extracts
were cleared by centrifugation at 13,000 rpm during 15 min at 4◦C. Proteins concentra-
tion was determined using BCA protein assay (Thermo Scientific Pierce, USA). Proteins
were separated by NuPAGE 10% Bis-Tris Gel (Invitrogen) and transferred to BA-S 85 ni-
trocellulose membrane (Schleicher & Schuell, GE Healthcare, UK). After blockage phase
with 5% milk in PBS containing 0.1% Tween-20, the membrane was probed over night
at 4◦C with rabbit anti-Fli1 (c term) antibody (Santa Cruz Biotechnology, USA) diluted
to 1/500 in 2.5% of milk in PBS containing 0.1% Tween-20. The first antibody was
detected using anti-rabbit antibody bounded to peroxidase (GE Healthcare) diluted to
1/1500 and revealed with chemiluminescence Kit (AmershamTM ECLTM, GE Healthcare).
Actin protein was used as housekeeping gene and was detected using anti actin antibody
(Sigma).
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Tables and Figures
Table 1: Physico-chemical characteristics of the two types of ND-polycation complex in
aqueous suspension compared to untreated ND.
Type of nanodiamonds Size Zeta Potential pH Amine content
(nm) (mV) (µmoles/g)
ND 54 -28 – –
ND-PAH 133 +31 5.6 274
ND-PEI 123 +27 6.7 173
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Figure 1: Titration of the binding of siRNA to NDs surface. Free siRNA concentration
is determined by ethidium bromide coloration after separation from NDs by centrifuga-
tion as described in the Experimental Section. Initial concentration of siRNA: 5 ng/µl,
corresponding to 384 nM.
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Figure 2: Cell viability measurements by MTT assay using NIH/3T3. The cells were
incubated with NDs and NDs coated with positive polymers with siRNA (50 nM) even-
tually bound to them for doses from 0.001 − 0.1 µgµl−1 for 24 h. Viability results are
presented in percent as the ratio of MTT for treated cells on MTT for untreated cells.
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Figure 3: Colocalization study between fND-PEI vectors (red channel, (a)), and siRNA
labeled by FITC (green channel, (b)), at siRNA:ND-PEI mass 1:75 ratio, in a NIH/3T3
EF cell. (c) Scattered plot of the green vs. red intensity of images (a) and (b) after
digitalization on 8-bits. (d) phase contrast image of a cell showing that nanodiamonds
are observed as aggregates in the perinuclear region. Observations made on cells fixed
at t = 24 h after the 4 h incubation with 50 nM siRNA, using a home-made confocal
microscope,17 equipped with a ×60, NA=1.4, oil microscope objective. Scale bar: 5 µm.
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Figure 4: Kinetic study of the release of siRNA in NIH/3T3 EF cell after their vectoriza-
tion by fND. siRNA is fluorescently labeled by FITC. Observations are done by confocal
microscopy (Leica TSC SPE) at different times (0, 6, 24, 48, 72) hours after an initial
4 h incubation of the cells with 50 nM siRNA vectorized by either (a) ND-PAH or (b)
ND-PEI at (1:25; 1 : 75) mass ratios. For each serie, the high panel (green channel) dis-
play the fluorescence of FITC (siRNA) and the down ones (red channel) the fluorescence
of fNDs. Nucleus is labelled with DAPI (blue channel superimposed to the green one)).
(c) Right figure: quantitative estimate of the siRNA release time, using the photolumi-
nescence intensity of FITC (FITC PL) over the whole cell, normalized to that of fNDs
(fND PL). The mean value of 5 to 20 cells is plotted. Scale bar: 10 µm.
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Figure 5: RT-qPCR of EWS-Fli1 gene expression in (a) NIH/3T3 EF cells or in (b) A673
cells treated by 50 nM siRNA vectorized by ND-PAH at mass ratio 1:25, or by ND-PEI
at ratio 1:75 or by lipofectamine as positive control. The EWS-Fli1 mRNA expression
(controlled by the siRNA with the Anti-Sense action, siRNA AS) is normalized to the
18S RNA of the same sample used as a control (siRNA CT). Dark grey bars for cells
treated in DMEM medium containing 10% foetal bovine serum. Light grey bars in (a)
correspond to cells treated in OptiMEM medium without serum. (c) Western blot assay
of EWS-Fli1 expression in A673 cells incubated during 24 h with 50 nM siRNA:ND-PAH
or ND-PEI at different weight ratios (1:w), where w value is indicated at the end of the
legend. “M” stands for medium alone, and the “Control” experiment (first data from the
left) was done on untreated A673 cells.
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Supporting information
Viabillity of cells expressing EWS-Fli1 oncogene after incubation
with siRNA:ND.
In addition to cell viability study on normal NIH/3T3 cells proving that the siRNA:ND-
polycation complex only weakly impacts the cell viability (see main text), we also studied
the viability of cells expressing EWS-Fli1 oncogene to proved that the viability is suffi-
ciently high not to impair the measurement of the efficiency of siRNA inhibition.
Murine fibroblast stably expressing human EWS-Fli1 oncogene (NIH/3T3 EF) and hu-
man Ewing sarcoma cells (A673) were treated by increasing concentrations of NDs,
cationic polymer coated NDs and siRNA bound to the cationic NDs. After 24 hours in-
cubation, survival of NIH/3T3 EF cells was determined by a MTT assay. Figure S1(a)
shows that ND alone present a low toxicity in the experimental conditions. Adsorption of
cationic polymers on ND increases their toxicity with an IC50 of 30 µgµl−1 for ND-PAH
and a toxicity of about 30% for ND-PEI at concentration higher than 15 µgµl−1. Sur-
prisingly, the toxicity does not increase with larger ND-PEI concentrations, which might
be due to the aggregation of the nanoparticles. When siRNA are adsorbed to ND-PAH
or ND-PEI (at 50 nM concentration), the toxicity decreases to around 20%, for concen-
trations larger than 10 µgµl−1. Similar results have been obtained with human A673
Ewing cells (Figure S1(b)). ND alone displays a low toxicity (less than 10%). Cationic
ND-PAH or ND-PEI are more toxic with IC50s of 8 µgµl−1 and 90 µgµl−1 respectively.
When siRNA are adsorbed onto the ND particles, we observe a decrease of their toxicity
with an IC50 of 20 µgµl−1 for ND-PAH and a constant 20% toxicity for concentrations
higher than 5 µgµl−1 for ND-PEI.
Note that the efficient inhibition of EWS-Fli1 oncogene was observed at ND-PEI con-
centration of 0.048 µgµl−1 (solid vertical arrow in Figure S1), at which a viability
larger than 70% for both cell lines is measured. Similarly, a viability fraction larger than
55% is obtained in the case of the ND-PAH carrier at the concentration of 0.016 µgµl−1
used in the inhibition experiment (vertical dashed arrow). At these optimal concentra-
tion the lipofectamine carrier yields a cell viability of about 55% for NIH/3T3 EF cells
(Figure S2).
Optimal mass of ND-polycation for a sufficient amount of siRNA:ND-
PAH/PEI internalized in NIH/3T3 EF cells in culture
We determined the optimal mass of ND-polycation for a sufficient amount of siRNA:ND-
PAH/PEI internalized in NIH/3T3 EF cells in culture using confocal microscopy raster
scans of fNDs and FITC-labelled siRNA fluorescence. As expected, Figure S3(b) and
Figure S3(c) show that the intracellular content of siRNA increases with the fND carrier
added mass, expressed as a ratio 1:w, for a given constant amount of siRNA (50 nM).
Moreover, the absence of FITC fluorescence in Figure S3(a) proves that siRNA alone
cannot enter the cells, justifying the need for a carrier.
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Figure S1: Cell viability measurements by MTT assay. (a) NIH/3T3 EF cells or (b)
A673 cells were incubated with ND and ND coated with cationic polymers with doses
from 0.001 to 0.1 µgµl−1 for 24 h, and siRNA concentration of 50 nM. Let us first point
out that the free antisens siRNA at concentration 50 nM does not impede the cellular
viability. Viability results are presented in percent as the ratio of MTT signal for treated
cells on the one of untreated cells, i.e. cells not incubated with ND or ND complexes.
Vertical dashed and solid arrows indicate the concentrations of ND-PAH (0.016 µgµl−1)
and ND-PEI (0.048 µgµl−1) respectively, which are used in EWS-Fli1 gene inhibition
experiment.
From a qualitative observation of Figure S3, one concludes that 1:25 and 1:75 are the
best siRNA:ND-PAH and siRNA:ND-PEI mass ratios respectively, among the one tested,
to achieve a sufficient amount of internalized siRNA. The corresponding ND-PAH and
ND-PEI concentrations of 0.016 µgµl−1 and 0.048 µgµl−1 respectively, were then selected
to test EWS-Fli1 gene inhibition at the same siRNA 50 nM concentration.
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Figure S2: Comparison of NIH/3T3 EF cell viability measured by MTT assay between
lipofectamine (no serum supplemented culture medium) and ND-polycation carriers, with
siRNA at 50 nM concentration. siRNA to ND-polycation mass ratios are 1:75 and 1:25
for siRNA:ND-PEI and siRNA:ND-PAH respectively, corresponding to 0.016 µg/µ and
0.048 µgµl−1 for the 50 nM siRNA concentration.
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Figure S3: Analysis by confocal microscopy of cell distribution of FITC-labeled siRNA
vectorized by fluorescent NDs in NIH/3T3 EF cells. The cells are incubated during 4
hours (a) with 50 nM siRNA alone, (b) with 50 nM siRNA vectorized by fND-PAH or
(c) with 50 nM siRNA vectorized by fND-PEI, at various siRNA:ND mass ratio 1 : w,
with w = 25, 50 or 75 corresponding to 0.016, 0.032 and 0.048 µgµl−1 ND-polymer
concentrations repectively. Observations are done on fixed cells. The cell nuclei are
colored with DAPI. Each of the 6 experiments is visualized twice for the same field:
siRNA (left panel, green and blue channel) and fND (right panel, red channel).Scale bar:
20 µm.
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